SBL

Sector: Pharma & Healthcare (Homeopathy Medicine)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

SBL operates in the pharma & healthcare segment of the Indian market, with a presence noted in the homeopathy medicine category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where SBL is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in homeopathy medicine includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

March - April 2026

The SBL Energy explosives manufacturing facility near Nagpur experienced a catastrophic blast on 1 March 2026, initially claiming 17 lives [5][6]. The death toll subsequently rose to 26 following the death of an additional worker [9]. Nine directors of SBL Energy were arrested in connection with the incident, with a case also registered against 21 officials [7][8]. Legal proceedings have intensified, with courts denying bail to five senior executives [4] and refusing bail to SBL officials while flagging major safety lapses [10]. The High Court granted bail to five individuals while rejecting the pleas of six others [2]. Investigations revealed that safety lapses, rather than regulatory failure, were the primary cause of the tragedy [3]. The incident is part of a broader pattern of industrial explosions in India during this period [1].

Sources (10)

1. At least 41 dead in two industrial explosions in India - Chemistry World · Chemistry World · Thu, 05 Mar 2026
2. HC Grants Bail To Five In SBL Blast Case, Rejects Pleas Of Six Others - The Times of India · The Times of India · Sun, 19 Apr 2026
3. SBL blast: Safety lapses, not regulatory failure, caused tragedy, HC told - The Indian Express · The Indian Express · Fri, 24 Apr 2026
4. SBL Energy blast: HC denies pre-arrest bail to five senior executives - ThePrint · ThePrint · Mon, 27 Apr 2026
5. 17 Killed In Blast At Explosives Manufacturing Company Near Nagpur - NDTV · NDTV · Sun, 01 Mar 2026
6. Nagpur Factory Blast: 17 Dead in SBL Energy Packing Unit - Deccan Herald · Deccan Herald · Sun, 01 Mar 2026
7. Nagpur blast: 9 SBL Energy directors arrested, case against 21 officials - The Federal · The Federal · Sun, 01 Mar 2026
8. Nagpur factory blast: Nine directors of explosives company arrested - The New Indian Express · The New Indian Express · Mon, 02 Mar 2026
9. One more SBL worker dies, blast toll 26 - The Times of India · The Times of India · Fri, 27 Mar 2026
10. Nagpur blast case: Court refuses bail to SBL officials, flags major safety lapses - The Indian Express · The Indian Express · Wed, 22 Apr 2026

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

SBL occupies a position in the homeopathy medicine category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on homeopathy medicine benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the homeopathy medicine value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

SBL is a participant in the Indian homeopathy medicine category, which forms part of the broader Pharma & Healthcare space. The Indian homeopathy medicine market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For SBL specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for SBL mirrors the broader homeopathy medicine category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for SBL as a peer benchmark within the homeopathy medicine category. For investors, lenders, or new entrant promoters seeking a fuller assessment of SBL, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with SBL?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (homeopathy medicine) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of SBL and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use SBL in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.